文献速递腹部CT

基于影像组学特征无创识别SOX9状态可能有助于构建肝细胞癌个体化治疗策略

Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2024-03-06

研究回顾性纳入2013年1月至2017年4月接受根治性切除后索拉非尼系统治疗的108例组织学证实肝细胞癌患者,从门静脉期CT提取影像组学特征构建评分,结合白蛋白-胆红素分级和肿瘤大小建立CLR模型预测SOX9阳性;CLR模型训练队列和验证队列AUC分别为0.912和0.790,SOX9阳性患者无复发生存率和总生存率显著低于阴性患者。

要点

  • CLR模型训练队列AUC 0.912、验证队列AUC 0.790,优于CL模型。
  • SOX9阳性患者1年无复发生存率51.02% vs 阴性75.00%,显著更低。
  • SOX9阳性患者2年总生存率76.92% vs 阴性94.94%,显著更低。

核心结论

  • 影像组学特征可能作为无创预测肝细胞癌SOX9状态的手段,并可能有助于构建个体化治疗策略。

研究设计与样本

  • 回顾性纳入2013年1月至2017年4月组织学证实肝细胞癌且根治性切除后接受索拉非尼系统治疗的患者108例,训练队列80例、验证队列28例;从术前门静脉期增强CT提取影像组学特征,以逻辑回归构建影像组学评分,经单因素和多因素分析建立CL模型和CLR模型。

诊断标准与关键数值

  • 多因素分析显示白蛋白-胆红素分级和肿瘤大小是预测SOX9阳性肝细胞癌的独立因素并纳入CL模型;CLR模型整合影像组学评分、白蛋白-胆红素分级和肿瘤大小,训练队列AUC 0.912、验证队列AUC 0.790。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop and validate a radiomics-based model for predicting SOX9-positive hepatocellular carcinoma (HCC) using preoperative contrast-enhanced computed tomography (CT) images.

METHODS: From January 2013 to April 2017, patients with histologically proven HCC who received systemic sorafenib treatment after curative resection were retrospectively enrolled. Radiomic features were extracted from portal venous phase CT images and selected to build a radiomics score using logistic regression analysis. The factors associated with SOX9 expression were selected and combined by univariate and multivariate analyses to establish clinico-liver imaging (CL) model and clinico-liver imaging-radiomics (CLR) model. Diagnostic performance was measured by area under curve (AUC). Overall survival (OS) and recurrence-free survival (RFS) rates were compared using Kaplan-Meier method.

RESULTS: A total of 108 patients (training cohort: n = 80; validation cohort: n = 28) were enrolled. Multivariate analyses revealed that the albumin-bilirubin grade and tumor size were significant independent factors for predicting SOX9-positive HCCs and were included in the CL model. The CLR model integrating the radiomics score with albumin-bilirubin grade and tumor size showed better discriminative performance than the CL model with AUCs of 0.912 and 0.790 in the training and validation cohorts. Survival curves for RFS and OS showed that SOX9 expression was closely related to the prognosis of HCC patients. RFS and OS rates were significantly lower in patients with SOX9-positive than SOX9-negative (51.02% vs. 75.00% at 1-year RFS rates; 76.92% vs. 94.94% at 2-year OS rates).

CONCLUSION: Radiomics signatures may serve as noninvasive predictors for SOX9 status evaluation in patients with HCC and may aid in constructing individualized treatment strategies.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Che F, Wei Y, Xu Q, et al. Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma. Abdom Radiol (NY). 2024. PMID: 38446180. doi:10.1007/s00261-024-04190-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。